Symbol
| BIK
| contributors: mct/pgu - updated : 10-06-2020
|
HGNC name
| BCL2-interacting killer (apoptosis-inducing)
|
HGNC id
| 1051
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
tumoral
| somatic mutation
|  
|  
|  
|
mutated in B-cell lymphomas | tumoral
|  
| deletion
|  
|  
|
chromosomal deletions encompassing BIK locus or epigenetic silencing in cancers | |
Variant & Polymorphism
|
| |
Candidate gene
Marker
| prognostic or therapeutic marker in breast cancer patients according to the estrogen receptor alpha expression | Therapy target
|
System | Type | Disorder | Pubmed |
cancer | | | |
prominent target for anti-cancers drugs that inhibit proteasomal functions | cancer | | | |
therapeutic molecule in gene therapy-based approaches to treat difficult cancers | cancer | | | |
blocking BIK degradation has the potential to be used as an anti-cancer strategy |
| | |